Menu
Search
|

Menu

Close
X

ImmunoGen Inc IMGN.OQ (NASDAQ Stock Exchange Global Select Market)

11.68 USD
-- (--)
As of Feb 21
chart
Previous Close 11.68
Open --
Volume --
3m Avg Volume 796,498
Today’s High --
Today’s Low --
52 Week High 12.04
52 Week Low 2.44
Shares Outstanding (mil) 112.22
Market Capitalization (mil) 768.71
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.10 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY17
115
FY16
54
FY15
86
EPS (USD)
FY17
-1.016
FY16
-1.676
FY15
-0.707
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.63
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-63.15
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Stephen McCluski
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Mark Enyedy
President, Chief Executive Officer, Director, Since 2016
Salary: $325,000.00
Bonus: $236,438.00
David Johnston
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $198,996.00
Bonus: $77,927.00
Richard Gregory
Executive Vice President - Research, Chief Scientific Officer, Since 2015
Salary: $223,237.00
Bonus: $87,419.00
Craig Barrows
Executive Vice President, General Counsel, Secretary, Since 2016
Salary: $297,250.00
Bonus: $87,927.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

830 WINTER ST
WALTHAM   MA   02451-1477

Phone: +1781.8950600

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

SPONSORED STORIES